Ayala Pharmaceuticals IncOTCQX US:ADXS
- LAST PRICE0.5400
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots---/ ---
- Ask / Lots---/ ---
- Open / Previous Close0.0000 / 0.5400
- Day Range---
- 52 Week Range
- Volume---
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | ADXS |
|---|---|---|
| 09:41 ET | 100 | 0.54 |
Mar 26, 2024
Press Release: Immunome Completes Acquisition of AL102, a Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala, from 8:01AM ET on Tuesday Mar 26, 2024 by Dow Jones
8:01AM ET on Tuesday Mar 26, 2024 by Dow JonesAyala Pharmaceuticals Announces Completion of Sale of AL102 to Immunome, from 8:00AM ET on Tuesday Mar 26, 2024 by Dow Jones
8:00AM ET on Tuesday Mar 26, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Ayala Pharmaceuticals Inc | 23.0M | -0.1x | --- |
Bioxytran Inc | 22.9M | -4.4x | --- |
Neurosense Therapeutics Ltd | 23.2M | -1.8x | --- |
Lisata Therapeutics Inc | 23.5M | -1.1x | --- |
Eom Pharmaceutical Holdings Inc | 22.4M | -4.6x | --- |
Bullfrog AI Holdings, Inc. | 22.5M | -3.2x | --- |
Company Information
Ayala Pharmaceuticals, Inc. is a clinical-stage oncology company primarily focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, primarily in genetically defined patient populations. The Company's lead candidate is aspacytarabine (BST-236), a novel anti-metabolite for first line treatment in unfit acute myeloid leukemia (AML). Aspacytarabine (BST-236) is composed of cytarabine covalently bound to asparagine, acting as a pro-drug of cytarabine. It is also focused on the development and commercialization of proprietary Listeria monocytogenes (Lm)-based antigen delivery products. These efforts are primarily focused on the development of ADXS-504, a Lm-based therapy for early-stage prostate cancer.
Contact Information
- Headquarters
- 9 DEER PARK DRIVE, SUITE K-1MONMOUTH JUNCTION, NJ, United States 08852
- Phone
- 732-545-1590
- Fax
- 302-674-5266
Executives
- Independent Chairman of the Board
- David Sidransky
- President, Chief Executive Officer, Director
- Kenneth Berlin
- Independent Vice Chairman of the Board
- Vered Bisker-Leib
- Chief Financial Officer
- Roy Golan
- Director
- Yuval Cabilly
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $23.0M |
|---|---|
Revenue (TTM) | $13.0K |
Shares Outstanding | 42.6M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.69 |
EPS | $-7.46 |
Book Value | $-2.06 |
P/E Ratio | -0.1x |
Price/Sales (TTM) | 1,770.9 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -278,969.20% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
